Drug combo has long-term efficacy

The safety and benefits of IDegLira, a combination of insulin degludec (IDeg) and liraglutide (Lira), are sustained for at least 12 months, according to trial results presented at the conference of the European Association for the Study of Diabetes (EASD 2014)  in Vienna.

The drug provided the advantages and mitigated the main side effects of each of its components, report the researchers, who include Australian endocrinologist Dr Sultan Linjawi.

These benefits had previously been sustained to 26 weeks among patients with type 2 diabetes who were randomised to once-daily IDegLira, IDeg or Lira (1.8 mg), plus metformin ± pioglitazone.

Of the 1,663 adults randomised in the main trial, 1,311 entered the extension. At the end of the Novo Nordisk-backed study, daily